Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02891850 · ClinicalTrials.gov registry record · Phase 4
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 225
- Enrollment target
NCT02891850 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 225 participants.
The verdict
NCT02891850, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 225 participants
- Enrollment target
Study Summary
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
Interventions
- DRUG Sildenafil
- DRUG Tadalafil
- DRUG Riociguat (Adempas, BAY63-2521)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2017-01-11 |
| Est. Completion | 2020-03-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02891850
The ClinicalTrials.gov registry entry for NCT02891850 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sildenafil is the first listed.
NCT02891850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02891850 about?
NCT02891850 is a clinical study titled "Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy". To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
What is the current status of trial NCT02891850?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 225 participants. The study started on 2017-01-11. Estimated completion is 2020-03-03.
What interventions are being tested in trial NCT02891850?
The interventions under investigation include: Sildenafil (DRUG), Tadalafil (DRUG), Riociguat (Adempas, BAY63-2521) (DRUG).
Who is sponsoring clinical trial NCT02891850?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.